EXTON, Pa.--(BUSINESS WIRE)--Adolor Corporation (NasdaqGM:ADLR) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,829,576 covering the use of ADL6906 (beloxepin), a small molecule, for the treatment of pain. The issued patent will expire on February 19, 2029.
